Poxvirus oncolytic virotherapy

Lino E. Torres-Domínguez, Douglas McFadden

Research output: Contribution to journalReview article

Abstract

Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Areas covered: Oncolytic poxviruses (Vaccinia virus and Myxoma virus) demonstrated encouraging results in multiple pre-clinical tumor models and some clinical trials for the treatment of various cancers. This review summarizes the advances made on poxvirus oncolytic virotherapy in the last five years. Expert opinion: Many challenges remain in poxvirus oncolytic virotherapy. Two key goals to achieve are enhancing the efficiency of viral delivery to tumor sites and overcoming local tumor immune-evasion. Additional efforts are necessary to explore the best combination of virotherapy with standard available treatments, particularly immunotherapies. By addressing these issues, this new modality will continue to improve as an adjunct biotherapy to treat malignant diseases.

Original languageEnglish (US)
Pages (from-to)561-573
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume19
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Oncolytic Virotherapy
Poxviridae
Tumors
Viruses
Neoplasms
Biological Therapy
Myxoma virus
Oncolytic Viruses
Tumor Escape
Vaccinia virus
Expert Testimony
Therapeutics
Cells
Immunotherapy
Immunity
Clinical Trials

Keywords

  • Myxoma virus
  • oncolytic
  • oncolytic virus
  • Vaccinia virus
  • virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Poxvirus oncolytic virotherapy. / Torres-Domínguez, Lino E.; McFadden, Douglas.

In: Expert Opinion on Biological Therapy, Vol. 19, No. 6, 03.06.2019, p. 561-573.

Research output: Contribution to journalReview article

Torres-Domínguez, Lino E. ; McFadden, Douglas. / Poxvirus oncolytic virotherapy. In: Expert Opinion on Biological Therapy. 2019 ; Vol. 19, No. 6. pp. 561-573.
@article{386c2f737cec4cc5a7abb35e72d1ec6a,
title = "Poxvirus oncolytic virotherapy",
abstract = "Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Areas covered: Oncolytic poxviruses (Vaccinia virus and Myxoma virus) demonstrated encouraging results in multiple pre-clinical tumor models and some clinical trials for the treatment of various cancers. This review summarizes the advances made on poxvirus oncolytic virotherapy in the last five years. Expert opinion: Many challenges remain in poxvirus oncolytic virotherapy. Two key goals to achieve are enhancing the efficiency of viral delivery to tumor sites and overcoming local tumor immune-evasion. Additional efforts are necessary to explore the best combination of virotherapy with standard available treatments, particularly immunotherapies. By addressing these issues, this new modality will continue to improve as an adjunct biotherapy to treat malignant diseases.",
keywords = "Myxoma virus, oncolytic, oncolytic virus, Vaccinia virus, virotherapy",
author = "Torres-Dom{\'i}nguez, {Lino E.} and Douglas McFadden",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/14712598.2019.1600669",
language = "English (US)",
volume = "19",
pages = "561--573",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Poxvirus oncolytic virotherapy

AU - Torres-Domínguez, Lino E.

AU - McFadden, Douglas

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Areas covered: Oncolytic poxviruses (Vaccinia virus and Myxoma virus) demonstrated encouraging results in multiple pre-clinical tumor models and some clinical trials for the treatment of various cancers. This review summarizes the advances made on poxvirus oncolytic virotherapy in the last five years. Expert opinion: Many challenges remain in poxvirus oncolytic virotherapy. Two key goals to achieve are enhancing the efficiency of viral delivery to tumor sites and overcoming local tumor immune-evasion. Additional efforts are necessary to explore the best combination of virotherapy with standard available treatments, particularly immunotherapies. By addressing these issues, this new modality will continue to improve as an adjunct biotherapy to treat malignant diseases.

AB - Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Areas covered: Oncolytic poxviruses (Vaccinia virus and Myxoma virus) demonstrated encouraging results in multiple pre-clinical tumor models and some clinical trials for the treatment of various cancers. This review summarizes the advances made on poxvirus oncolytic virotherapy in the last five years. Expert opinion: Many challenges remain in poxvirus oncolytic virotherapy. Two key goals to achieve are enhancing the efficiency of viral delivery to tumor sites and overcoming local tumor immune-evasion. Additional efforts are necessary to explore the best combination of virotherapy with standard available treatments, particularly immunotherapies. By addressing these issues, this new modality will continue to improve as an adjunct biotherapy to treat malignant diseases.

KW - Myxoma virus

KW - oncolytic

KW - oncolytic virus

KW - Vaccinia virus

KW - virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85066918090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066918090&partnerID=8YFLogxK

U2 - 10.1080/14712598.2019.1600669

DO - 10.1080/14712598.2019.1600669

M3 - Review article

VL - 19

SP - 561

EP - 573

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -